Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2965295 | 0.76 | KDM4E (0.36) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL121645 | 0.76 | KDM4E (0.36) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16179 | 0.76 | KDM4E (0.36) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL8071921 | 0.74 | KDM4E (0.35) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20526419 | 0.74 | KDM4E (0.35) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL11520833 | 0.74 | KDM4E (0.35) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| Cyclohexane SCHEMBL23674788 | 0.71 | KDM4E (0.33) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3556 | 0.70 | — | — | |
| SCHEMBL630371 | 0.68 | — | — | |
| SCHEMBL448708 | 0.65 | KDM4E (0.35) | KDM4EMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 925 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762377-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | Cook, Timothy, H. (US) | 2021-01-13 | — | — | EP | claimed |
| WO-2019173790-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | HLA TIMOTHY (US) | 2019-09-12 | — | — | WO | claimed |
| US-9181261-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2015-11-10 | — | — | US | claimed |
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | US | claimed |
| EP-2858501-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Merck Sharp & Dohme Corp. (US) | 2015-04-15 | — | — | EP | claimed |
| WO-2013176970-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2013-11-28 | — | — | WO | claimed |
| EP-2336131-A1 | Hydantoin compounds | Eisai R&D Management Co., Ltd. (JP) | 2011-06-22 | — | — | EP | claimed |
| US-20100113446-A1 | HYDANTOIN COMPOUNDS | GALLAGHER JR BRIAN M | 2010-05-06 | — | — | US | claimed |
| WO-2010039186-A2 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-04-08 | — | — | WO | claimed |
| US-7666875-B2 | 1,3,8-triazaspiro(4,5)decane derivatives; antiinflammatory agent for treating rheumatoid arthritis, allergic, multiple sclerosis, autoimmune disease such as inflammatory bowel disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | claimed |
| WO-2004043369-A2 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | claimed |
| WO-2004043917-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | claimed |
| EP-1399137-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | claimed |
| EP-1387679-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-11 | — | — | EP | claimed |
| EP-1385830-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| EP-1385841-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2002090353-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| WO-2002089793-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| WO-2002090337-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| WO-2002089785-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | NGF, NGFR, NTRK1 | KDM4E 3171/4885MEN1 4670/4885ALDH1A1 4641/4885 |
| US-20100113446-A1 | HYDANTOIN COMPOUNDS | HNMT, HLA-DRB1, SSB | KDM4E 1585/4885MEN1 699/4885ALDH1A1 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.